FERRIPROX
Drug
CHIESI USA, INC.
Total Payments
$760,853
Transactions
955
Doctors
499
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $50,170 | 189 | 157 |
| 2023 | $191,567 | 261 | 150 |
| 2022 | $214,310 | 142 | 105 |
| 2021 | $115,214 | 115 | 87 |
| 2020 | $94,814 | 122 | 52 |
| 2019 | $93,859 | 72 | 45 |
| 2017 | $920.33 | 54 | 40 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $355,011 | 132 | 46.7% |
| Grant | $210,520 | 5 | 27.7% |
| Unspecified | $71,907 | 19 | 9.5% |
| Honoraria | $61,751 | 33 | 8.1% |
| Food and Beverage | $23,517 | 665 | 3.1% |
| Travel and Lodging | $19,975 | 84 | 2.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,023 | 7 | 2.4% |
| Education | $149.30 | 10 | 0.0% |
Payments by Type
General
$688,946
936 transactions
Research
$71,907
19 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| LA38-EXT | APO-PHARMA INC. | $36,845 | 0 |
| LA38-0411 FIRST | APO-PHARMA INC. | $30,040 | 0 |
| LA55-0417 START Study | APO-PHARMA INC. | $5,023 | 0 |
Top Doctors Receiving Payments for FERRIPROX
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Oakland, CA | $282,427 | 24 |
| , MD | Pediatric Hematology-Oncology | Chicago, IL | $54,449 | 31 |
| , MD | Pediatric Hematology-Oncology | Los Angeles, CA | $22,567 | 15 |
| Amer Zeidan | Hematology & Oncology | New Haven, CT | $21,750 | 9 |
| , MD | Pediatrics | Ann Arbor, MI | $18,613 | 17 |
| , MD | Internal Medicine | Durham, NC | $17,765 | 12 |
| , M.D | Pediatrics | Philadelphia, PA | $16,993 | 5 |
| , MD | Pediatric Hematology-Oncology | Minneapolis, MN | $16,456 | 13 |
| , MD | Pediatric Hematology-Oncology | Washington, DC | $13,140 | 3 |
| , MD | Pediatric Hematology-Oncology | New Hyde Park, NY | $11,144 | 8 |
| , MD | Pediatric Hematology-Oncology | Birmingham, AL | $11,091 | 7 |
| Richard Drachtman | Pediatrics | New Brunswick, NJ | $10,034 | 20 |
| , M.D | Pediatrics | Philadelphia, PA | $9,605 | 5 |
| , M.D | Clinical Biochemical Genetics | New York, NY | $9,350 | 2 |
| , M.D., PH.D | Pediatric Hematology-Oncology | Winston Salem, NC | $8,675 | 9 |
| , M.D | Pediatric Hematology-Oncology | Los Angeles, CA | $8,501 | 8 |
| , MD | Blood Banking & Transfusion Medicine | Saint Louis, MO | $8,425 | 8 |
| , M.D | Hematology | Houston, TX | $8,352 | 7 |
| Susan Carson | Pediatric Hematology-Oncology | Los Angeles, CA | $8,329 | 15 |
| , M.D | Hematology & Oncology | Chicago, IL | $7,847 | 3 |
| , M.D | Pediatric Hematology-Oncology | San Diego, CA | $7,830 | 2 |
| , M.D | Clinical Genetics (M.D.) | Cincinnati, OH | $7,518 | 2 |
| , NP | Pediatrics | Washington, DC | $7,083 | 14 |
| , MD PHD | Clinical Cytogenetics | Winfield, IL | $6,725 | 2 |
| , MD | Pediatric Hematology-Oncology | Aurora, CO | $5,744 | 10 |
Ad
Manufacturing Companies
- Chiesi USA, Inc. $571,261
- CHIESI USA, INC. $94,814
- APO-PHARMA INC. $94,162
- APO-PHARMA USA, INC. $616.92
Product Information
- Type Drug
- Total Payments $760,853
- Total Doctors 499
- Transactions 955
About FERRIPROX
FERRIPROX is a drug associated with $760,853 in payments to 499 healthcare providers, recorded across 955 transactions in the CMS Open Payments database. The primary manufacturer is CHIESI USA, INC..
Payment data is available from 2017 to 2024. In 2024, $50,170 was paid across 189 transactions to 157 doctors.
The most common payment nature for FERRIPROX is "Consulting Fee" ($355,011, 46.7% of total).
FERRIPROX is associated with 3 research studies, including "LA38-EXT" ($36,845).